Our data suggest that not only concurrent antiandrogen therapy but also GABBR2 inhibitor treatment has the potential of being a means of chemosensitization, especially in patients with AR/GABBR2-positive bladder tumor. The gene discussed is AR; the disease is urinary bladder neoplasm.